Attanasio Roberto, Epaminonda Paolo, Motti Enrico, Giugni Enrico, Ventrella Laura, Cozzi Renato, Farabola Mario, Loli Paola, Beck-Peccoz Paolo, Arosio Maura
Division of Endocrinology, Ospedale Niguarda, Milan, Italy.
J Clin Endocrinol Metab. 2003 Jul;88(7):3105-12. doi: 10.1210/jc.2002-021663.
Stereotactic radiosurgery by gamma-knife (GK) is an attractive therapeutic option after failure of microsurgical removal in patients with pituitary adenoma. In these tumors or remnants of them, it aims to obtain the arrest of cell proliferation and hormone hypersecretion using a single precise high dose of ionizing radiation, sparing surrounding structures. The long-term efficacy and toxicity of GK in acromegaly are only partially known. Thirty acromegalic patients (14 women and 16 men) entered a prospective study of GK treatment. Most were surgical failures, whereas in 3 GK was the primary treatment. Imaging of the adenoma and target coordinates identification were obtained by high resolution magnetic resonance imaging. All patients were treated with multiple isocenters (mean, 8; range, 3-11). The 50% isodose was used in 27 patients (90%). The mean margin dose was 20 Gy (range, 15-35), and the dose to the visual pathways was always less than 8 Gy. After a median follow-up of 46 months (range, 9-96), IGF-I fell from 805 micro g/liter (median; interquartile range, 640-994) to 460 micro g/liter (interquartile range, 217-654; P = 0.0002), and normal age-matched IGF-I levels were reached in 7 patients (23%). Mean GH levels decreased from 10 micro g/liter (interquartile range, 6.4-15) to 2.9 micro g/liter (interquartile range, 2-5.3; P < 0.0001), reaching levels below 2.5 micro g/liter in 11 (37%). The rate of persistently pathological hormonal levels was still 70% at 5 yr by Kaplan-Meier analysis. The median volume was 1.43 ml (range, 0.20-3.7). Tumor shrinkage (at least 25% of basal volume) occurred after 24 months (range, 12-36) in 11 of 19 patients (58% of assessable patients). The rate of shrinkage was 79% at 4 yr. In no case was further growth observed. Only 1 patient complained of side-effects (severe headache and nausea immediately after the procedure, with full recovery in a few days with steroid therapy). Anterior pituitary failures were observed in 2 patients, who already had partial hypopituitarism, after 2 and 6 yr, respectively. No patient developed visual deficits. GK is a valid adjunctive tool in the management of acromegaly that controls GH/IGF-I hypersecretion and tumor growth, with shrinkage of adenoma and no recurrence of the disease in the considered observation period and with low acute and chronic toxicity.
对于垂体腺瘤患者,显微手术切除失败后,伽玛刀立体定向放射外科治疗(GK)是一种有吸引力的治疗选择。在这些肿瘤或其残余组织中,它旨在通过单次精确高剂量的电离辐射来抑制细胞增殖和激素分泌过多,同时保护周围结构。GK治疗肢端肥大症的长期疗效和毒性仅部分为人所知。30例肢端肥大症患者(14名女性和16名男性)进入了GK治疗的前瞻性研究。大多数患者手术失败,而3例患者中GK是主要治疗方法。通过高分辨率磁共振成像获得腺瘤的影像学资料并确定靶坐标。所有患者均采用多个等中心治疗(平均8个;范围3 - 11个)。27例患者(90%)使用了50%等剂量线。平均边缘剂量为20 Gy(范围15 - 35),视路剂量始终小于8 Gy。中位随访46个月(范围9 - 96个月)后,胰岛素样生长因子I(IGF - I)从805μg/升(中位数;四分位间距,640 - 994)降至460μg/升(四分位间距,217 - 654;P = 0.0002),7例患者(23%)达到了年龄匹配的正常IGF - I水平。平均生长激素(GH)水平从10μg/升(四分位间距,6.4 - 15)降至2.9μg/升(四分位间距,2 - 5.3;P < 0.0001),11例患者(37%)的GH水平降至2.5μg/升以下。根据Kaplan - Meier分析,5年后持续存在病理性激素水平的比例仍为70%。中位体积为1.43 ml(范围0.20 - 3.7)。19例患者中的11例(可评估患者的58%)在24个月(范围12 - 36个月)后出现肿瘤缩小(至少为基础体积的25%)。4年后缩小率为79%。未观察到进一步生长的情况。仅1例患者抱怨有副作用(术后立即出现严重头痛和恶心,经类固醇治疗数天后完全恢复)。2例患者分别在2年和6年后出现垂体前叶功能减退,这2例患者原本就有部分垂体功能减退。没有患者出现视力障碍。GK是肢端肥大症治疗中一种有效的辅助工具,可控制GH/IGF - I分泌过多和肿瘤生长,在观察期内腺瘤缩小且疾病无复发,急性和慢性毒性低。